Integrity Alliance LLC. Takes Position in Cardiol Therapeutics Inc. $CRDL

Integrity Alliance LLC. purchased a new position in Cardiol Therapeutics Inc. (NASDAQ:CRDL) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 435,025 shares of the company’s stock, valued at approximately $416,000. Integrity Alliance LLC. owned 0.39% of Cardiol Therapeutics as of its most recent SEC filing.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Tejara Capital Ltd lifted its stake in Cardiol Therapeutics by 95.1% in the fourth quarter. Tejara Capital Ltd now owns 5,130,122 shares of the company’s stock worth $4,893,000 after acquiring an additional 2,500,000 shares during the period. Boyer Financial Services Inc. purchased a new stake in Cardiol Therapeutics in the fourth quarter worth $33,000. Virtu Financial LLC purchased a new stake in Cardiol Therapeutics in the third quarter worth $154,000. Bank of America Corp DE lifted its position in Cardiol Therapeutics by 1,983.0% during the third quarter. Bank of America Corp DE now owns 551,053 shares of the company’s stock valued at $590,000 after buying an additional 524,598 shares during the period. Finally, Citadel Advisors LLC lifted its position in Cardiol Therapeutics by 1,132.6% during the third quarter. Citadel Advisors LLC now owns 463,462 shares of the company’s stock valued at $496,000 after buying an additional 425,862 shares during the period. Hedge funds and other institutional investors own 12.49% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on the company. raised Cardiol Therapeutics to a “strong-buy” rating in a research report on Tuesday, February 3rd. Canaccord Genuity Group reaffirmed a “buy” rating and issued a $8.00 price target on shares of Cardiol Therapeutics in a research report on Monday, April 6th. Wall Street Zen lowered Cardiol Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, May 16th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $9.00 price target on shares of Cardiol Therapeutics in a research report on Tuesday, February 10th. Two equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Hold” and an average price target of $8.50.

Cardiol Therapeutics Stock Down 4.7%

Cardiol Therapeutics stock opened at $1.22 on Friday. The business has a 50-day simple moving average of $1.32 and a two-hundred day simple moving average of $1.12. The company has a market cap of $136.42 million, a P/E ratio of -4.36 and a beta of 0.77. Cardiol Therapeutics Inc. has a 52-week low of $0.88 and a 52-week high of $1.71.

Cardiol Therapeutics (NASDAQ:CRDL) last released its quarterly earnings results on Monday, May 11th. The company reported ($0.07) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.07). Research analysts anticipate that Cardiol Therapeutics Inc. will post -0.31 EPS for the current fiscal year.

Cardiol Therapeutics Company Profile

Cardiol Therapeutics Inc (NASDAQ: CRDL) is a clinical-stage pharmaceutical company dedicated to developing immunomodulatory treatments for patients with cardiovascular disease. The company’s lead asset, CardiolRx, is a proprietary, pharmaceutical-grade cannabidiol (CBD) formulation designed to target the inflammation and oxidative stress underlying conditions such as acute myocardial injury and heart failure. Cardiol holds exclusive global rights to CardiolRx through a licensing partnership and is advancing additional preclinical programs focused on small-molecule immunotherapies for heart disease.

CardiolRx is formulated for oral administration and has been evaluated in a randomized, placebo-controlled Phase 2 myocardial protection study assessing safety and key biomarkers following acute coronary syndromes.